Dossier assessment

Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-88
Last updated

Report documents

  1. Extract of dossier assessment

    Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 702 kB, EN, not accessible
  2. Dossier assessment

    Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible

Dossier assessment

Indication:

Adults with previously untreated chronic lymphocytic leukaemia (CLL)

Result of dossier assessment:

Patients in good general health for whom therapy with fludarabine + cyclophosphamide + rituximab is an option: indication of major added benefit. Other research questions: added benefit not proven.

Press releases

Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR

The new drug combination prolongs overall survival in patients in good general health. No study data are available for other patient groups.

Project details

Project no.
A20-88
Commission
Commission awarded on 01.10.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-78
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-77
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-60
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-39
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Ibrutinib - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-04
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)

    Project no.
    G14-11
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-04
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form